/

ARTL

Artelo Biosciences, Inc.Closed

2.98−0.13 −4.18%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.97 −0.34%

Open

3.11

Prev close

3.11

Day range

2.933.12

52-week range

2.93179.19

Volume

30.74K0.06×

Mkt cap

1.63M

P/E ttm

—

Fwd P/E

-3.39

EPS ttm

-130.56

Div yield

0.00%

Earnings

—

From 52w high

−98.34%

Price Chart

Yahoo Finance · delayed

ARTLOct 13, 2026O 3.11H 3.12L 2.92C 2.98−0.13 (−4.18%)Vol 30.80K

SMA 505.37
SMA 20024.05

1Y change −97.33% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ARTL Artelo Biosciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −13.87%
1 month: −45.12%
3 months: −71.46%
6 months: −93.88%
Year to date: −90.95%
1 year: −97.33%

Valuation & ownership

Market cap: 1.63M
Enterprise value: −2.63M
P/E (ttm): —
Forward P/E: -3.39
PEG ratio: —
Price / book: 0.28
Price / sales (ttm): —
EV / EBITDA: —
EPS (ttm): -130.56
EPS (forward): -0.8800
Beta (5y monthly): -0.07
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 547.77K
Float: 510.24K
Short % of float: 8.43%
Short ratio (days): 0.04
Held by insiders: 0.11%
Held by institutions: 2.38%
Avg volume (3m): 487.97K
50-day average: 5.44
200-day average: 24.25
52-week change: −97.33%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 33.8
vs 50-day SMA: −44.47%
vs 200-day SMA: −87.61%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 24.88%
Realised vol (20d, ann.): 279.4%
From 52-week high: −98.34%
From 52-week low: +2.05%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About Artelo Biosciences, Inc.

Yahoo Finance profile

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 7
Headquarters: Solana Beach, CA, United States
Website: artelobio.com
Officers: Mr. Gregory D. Gorgas M.B.A. President, CEO, Secretary & Director
Mr. Mark E. Spring CPA CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer
Dr. Andrew Yates Ph.D.

SEAS

Seasonality · ARTL

2019–2026 · monthly returns

Strongest month Jun +17.69%Weakest month Oct −18.99%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	40.2	-30.4	112.3	-54.0	-59.9	-20.0	-31.3	-8.2	-36.5	-26.2			−91.0%
2025	13.2	-10.8	-18.2	12.0	7.1	110.6	-10.6	-22.0	-50.4	-32.5	-43.9	-29.9	−80.8%
2024	0.0	10.0	-3.9	-7.0	-0.4	-2.2	0.7	-3.7	-13.8	3.0	-9.0	1.0	−24.3%
2023	11.4	-11.0	-19.0	-29.7	9.6	11.4	-3.0	-1.6	-23.2	-15.4	11.7	1.4	−51.6%
2022	-19.1	-5.5	13.4	-15.1	-13.4	-4.2	7.3	-24.5	-10.4	-16.8	-14.3	17.5	−62.9%
2021	31.2	92.1	-11.4	-19.0	-6.1	-4.0	-16.0	-8.9	-13.2	-9.5	-12.0	-17.6	−28.9%
2020	-24.8	-47.3	-10.3	22.9	8.5	-5.5	-5.0	-16.5	3.4	-53.9	34.1	18.9	−73.0%
2019							-28.5	-40.7	10.8	-7.9	22.5	10.7	−41.3%

INSD

Insider Activity · ARTL

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Oct 27, 2025	Matsui Connie LDirector	Conversion of Exercise of derivative security at price 3.55 per share.	38.3K	$136.13K
Oct 27, 2025	Favorito Tamara A.Director	Conversion of Exercise of derivative security at price 3.55 per share.	6.8K	$24.30K
Oct 27, 2025	Gorgas Gregory DChief Executive Officer	Conversion of Exercise of derivative security at price 3.55 per share.	9.6K	$34.03K
Oct 27, 2025	Favorito Tamara A.Director	Conversion of Exercise of derivative security at price 3.55 per share.	6.8K	$24.30K

ARTL

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ARTL

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Artelo Biosciences, Inc.

Seasonality · ARTL

Insider Activity · ARTL

Congress Trades · ARTL

Investors Holding ARTL

Investors Holding ARTL

Congress Trades · ARTL

Insider Activity · ARTL

Seasonality · ARTL

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Artelo Biosciences, Inc.

Earnings & Dividends

News